Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Lankenau Institute for Medical Research has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The institute's current prosecution activity is confined to 1 distinct examiner and 1 distinct art unit. This alignment indicates a narrow research focus or a specific biotechnological innovation currently undergoing review. The limitation to 1 distinct art unit further emphasizes the specialized nature of the pending application.
The busiest examiner, STONEBRAKER, ALYSSA RAE, is responsible for 1 busiest examiner pending action. As the total pending office actions and the busiest examiner pending count are each 1, this official is the sole point of contact for the institute's active patent matters. Practitioners should focus their efforts on the specific examination history of this examiner to anticipate potential hurdles. The presence of only 1 distinct examiner means that the outcome of the current portfolio depends on the specific interpretation of biotechnology-focused patent law by STONEBRAKER, ALYSSA RAE.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STONEBRAKER, ALYSSA RAE | 1 | 58.9% | +49.4% |
| BELLAH, JEFFREY LAWRENCE | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17642108 | METHODS AND COMPOSITIONS FOR ASSESSING AND PREDICTING THERAPEUTIC RESPONSE | BELLAH, JEFFREY LAWRENCE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18004618 | COMPOSITIONS COMPRISING ANTIBODIES TO HUMAN IDO-2 | STONEBRAKER, ALYSSA RAE | 8d overdue |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18004618 | COMPOSITIONS COMPRISING ANTIBODIES TO HUMAN IDO-2 | STONEBRAKER, ALYSSA RAE | 1642 | §112 | Final Rejection | 8d overdue | Pending | Jan 06, 2023 |
| 17642108 | METHODS AND COMPOSITIONS FOR ASSESSING AND PREDICTING THERAPEUTIC RESPONSE | BELLAH, JEFFREY LAWRENCE | 1683 | §101§102§103§112 | Final Rejection | — | Pending | Mar 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLankenau Institute for Medical Research has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Alyssa Rae Stonebraker has the most, with 1 of Lankenau Institute for Medical Research's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
